What triggered GSK shares' latest price pullback

Traders Union
All News
Financial News
Gsk slips 2.09% today to gbx1939.50

Highlights

GSK completed a £2 billion share buyback and reaffirmed 2026 guidance for 7–9% core profit and EPS growth.
The Nuvalent acquisition is expected to slightly reduce core EPS in 2026–2028 but boost operating profit by 2027 and core EPS by 2029.
Technicals indicate short-term selling pressure but medium- and long-term bullish trends, with GBX1,943 as key resistance and a high probability of movement toward GBX1,980.

Buyback expansion and deal activity sustain guidance amid selling pressure

GSK completed a £2 billion share buyback program, acquiring over one million shares at an average price of approximately 1,953 pence per share and bringing its treasury holdings to 270.9 million shares, representing 6.7% of voting rights. The company reaffirmed its 2026 guidance, expecting core operating profit and core EPS to rise by 7%–9%, and maintained its dividend forecast at 70p per share. GSK also launched a formal tender offer to acquire Nuvalent Inc., expecting a modest reduction in core EPS from 2026 to 2028 but positive contributions to operating profit in 2027 and to core EPS in 2029. These updates were reported, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, points out that GSK’s 2.09% drop despite completing its £2 billion buyback reflects lingering skepticism. He notes persistent selling pressure and volatile sentiment, even as GSK maintains its guidance and dividend. The short-lived optimism from share repurchases has failed to offset broader market caution. Technical signals appear conflicted, with the MACD and oscillators contradicting the mixed momentum. "With uncertain trend signals and a failed post-buyback rally, I’d approach GSK with strict risk controls for now."

Viktoras Karapetjanc, expert at Traders Union, sees GSK’s fundamentals as increasingly robust following the major buyback and Nuvalent tender offer. He believes the reaffirmed 2026 guidance signals management confidence, and new M&A activity enhances long-term operating leverage. The high proportion of buy signals and buyer dominance reflect underlying market optimism. "GSK’s bullish structure remains intact — further growth is anticipated as the market digests positive strategic updates and sustained capital returns."

Parshwa Turakhiya, analyst, highlights mixed technical momentum and near-term volatility around GBX1,943. He sees opportunities for tactical trades within the defined range, given the strong buy signal cluster but lingering session lows. Short-term sentiment may drive rapid moves if support or resistance breaks. "Momentum shifts favor active setups over passive holding — traders should watch for a break above GBX1,943 or a slide below GBX1,937 in coming sessions."

Short-term support holds as bullish signals clash with volatility

GSK is trading just below its 20-day moving average (GBX1,943), but remains above the 50-day (GBX1,933) and 200-day (GBX1,885) levels, with the Ichimoku Kijun (GBX1,907) providing support. Immediate resistance is located at GBX1,943, while key support stands at GBX1,937. Momentum signals are mixed: the MACD signals a Buy, but the ADX reflects an uncertain trend. The RSI and CCI are both bullish, while the Stochastic RSI remains neutral. Bull/Bear Power is high at 49.1, pointing to ongoing buyer dominance, although the overbought reading warrants caution. The Awesome Oscillator supports further upside. GSK opened with a downside gap of about GBX5 (gap_pct -0.25%) and is near the session low, slipping GBX41.5 or 2.09%. Intraday volatility is 2.81%. Recent action points to continued selling pressure and mixed momentum that requires careful attention.

Previously it was reported that GSK’s active capital allocation strategy and recent M&A activity created a favorable backdrop for potential upside in the stock. The current action highlights persistent selling pressure despite strong buy signals, making the upcoming test of support at GBX1,937 a critical level for gauging near-term direction.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.